Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Microbiotix, Inc.
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
During the annual BIO International conference in June, researchers from the UK – which has pushed antimicrobial resistance to front and center on the global stage – discussed ongoing efforts for incentivizing antibiotic discovery and development, and the challenges that remain when it comes to management and resolution of the world’s AMR crisis.
The time for talking is over when it comes to antimicrobial resistance, says Jim O'Neill, urging the government to 'rediscover the passion for championing' initiatives in the UK, notably the new AMR Centre in Alderley Park near Manchester.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.